Deep-pocketed investors have adopted a bearish approach towards Capricor Therapeutics CAPR, and it's something market players ...

We recently looked at Goldman Sachs’ List Of Stocks That Hedge & Mutual Funds Love & Hate: 28 Stocks On The Mutual and Hedge ...

We recently published a list of 10 Best Depressed Stocks To Buy Heading into 2025. In this article, we are going to take a ...

In one of our recent articles about 10 High Growth Non-Tech Stocks That Are Profitable in 2024, we talked about how the US ...

Moderna is focusing on respiratory vaccines to sustain revenue streams amid COVID-19 declines. See more on MRNA stock and its ...

Looking at options history for Moderna MRNA we detected 21 trades. If we consider the specifics of each trade, it is accurate ...

New non-human primate data show highly selective in vivo delivery of mRNA to T cells with a cell-targeted lipid nanoparticle ...

Zylem Biosciences announced that Northwestern University has filed a lawsuit against Moderna (MRNA), alleging infringement of key patents ...

The latest trading session saw Moderna (MRNA) ending at $53.80, denoting a -0.55% adjustment from its last day's close. The stock's performance was behind the S&P 500's daily loss of 0.18%. Elsewhere, ...

CAMBRIDGE, Mass. and VANCOUVER, British Columbia and BASEL, Switzerland, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: ...

CAMBRIDGE, Mass. and VANCOUVER, British Columbia and BASEL, Switzerland, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, and Genevant ...

The large inflow of cash from Comirnaty gross profits in 2021-22 has further secured BioNTech's financial health. Outside of BioNTech’s covid-19 vaccine candidates, we think the earliest approval ...